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Clinical Trials
Darbepoetin May Improve Exercise Tolerance in CHF
Anemia often co-existswith congestive heart failure; reversing anemiamay improveexercise tolerance. Ponikowski and colleagues randomized 41 patients to either
darbepoetin (with a targeted hemoglobin between 12 and 15 g/dl) or placebo. There
were mild, nonstatistically significant improvements in peak VO2 and exercise dura-
tion. There was a significant improvement in the self-reported patient global assess-
ment, but no significant differences in heart failure–specific questionnaires. This small
study suggests that increasing hemoglobin levels with darbepoetinmaymildly improve
exercise duration and patient well-being for subjects with congestive heart failure and
reduced systolic function. See page 753. See figure.
Page 767
Interventional Cardiology
Successful Stenting of Carotid Total Occlusions
Previous studies have shown that surgical bypass of chronic carotid artery occlusionsdoes not improve outcomes. Kao and colleagues report on their experience in
opening these arteries with percutaneous techniques in patients with symptomatic
carotid occlusions. The procedure was attempted in 30 patients, and the lesion was
successfully crossed and dilated in 73%. There was one fatal periprocedural cerebro-
vascular accident, which was felt to be unrelated to the procedure, but no other
complications. There was evidence of hemodynamic improvement with reversal of
flow in the opthalmic artery in 80% of patients who were successfully opened.
Although technically challenging, this study suggests that chronic carotid occlusions
can be percutaneously treated. See page 765. See figure.
Heart Failure
Beta-Blockers May Improve Ventricular Dyssynchrony
Beta-blockers confer substantial improvements in cardiac function and symptomsof heart failure, but little is known about their effect on ventricular dyssynchrony.
Takemoto and colleagues studied patients with idiopathic dilated cardiomyopathies
and normal QRS using both tissue Doppler and strain echocardiography. Initial
studies confirmed that there is a substantial dyssynchrony between peakmovements of
thewalls of the ventricle, evenwhen theQRS is120ms. After 6months of carvedilol
therapy, there were significant improvements in ejection fraction, ventricular size, and
measurements of dyssynchrony. These improvements in global and regional mechan-
ical function may underlie the beneficial effects of carvedilol therapy and obviate the
need for electrical resynchronization in certain heart failure patients. See page 778.
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Heart Failure
Small Wireless Transmitter Accurately Measures PA Pressures
Rozenman and colleagues describe a novel, implantable pressure transducer thatcan be permanently implanted in the pulmonary artery. The device is delivered
percutaneously and anchored to the wall of the pulmonary artery via a self-expanding
nitinol platform. The implanted unit is small, and it sends a recording to an external
device using acoustic waves, rather than electromagnetic waves, thereby reducing
interference, attenuation, and energy requirements. There was good correlation with
standard Milar catheters and no evidence of rejection on histologic examination in
animal models. This device may prove useful for quickly, accurately, and serially
measuring pulmonary artery pressures, and it may prove useful for both in- and
outpatient management. See page 784. See figure.
Patent Foramen and Stroke
PFO May Not Increase Stroke Risk
Several lines of evidence suggest that patent foramen ovales (PFOs) may increase the
risk of ischemic stroke, but themagnitude of the increased risk is not known.DiTullio
and colleagues studied over 1,000 subjects with no previous stroke and performed
transthoracic echocardiograms with contrast injection. The prevalence of PFO was
15% in this community-based cohort, and over the next 8 years, 6% of subjects had a
stroke. The relative risk of stroke for those with a PFO was 1.6, which was not
statistically significant. This study suggests that the overall risk of stroke associatedwith
a PFO is low; more studies may be needed to identify those patients with a PFO at
increased risk. See page 797.
